SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

The upcoming SpaceX IPO is driving intense speculation, with market participants debating whether the anticipated debut will trigger a sector-wide rally or result in an overpriced "pump and dump" event. Investors are actively rotating between broader space competitors and specific pre-IPO proxies while questioning the valuation impacts on associated companies like Tesla.

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Stryker Corp.

Stryker Corp is facing intense community scrutiny and negative sentiment following a major cybersecurity incident that has triggered class-action lawsuits and concerns over massive potential liabilities related to HIPAA data breaches. While some investors view the recent price volatility as a buying opportunity based on strong historical fundamentals, others are actively betting against the company, citing deep operational disruptions and the risk of long-term structural damage.

WorldFinancial

WorldFinancial (WLFI) is seeing intense community debate as holders weigh a controversial governance proposal to lock up and burn billions of tokens against allegations of mismanagement and legal conflicts with high-profile crypto investors. The stock is trending due to these conflicting signals of a potential supply shock versus ongoing concerns regarding the project's long-term sustainability and leadership.

Amplify ETF Trust - Amplify Junior Silver Miners ETF

Amplify Junior Silver Miners ETF

Amplify Junior Silver Miners ETF (SILJ) is trending as investors aggressively discuss the sector's potential for a massive catch-up rally, driven by a persistent silver supply deficit and soaring industrial demand. While the community debates whether the metal's recent volatility signals a temporary correction or a long-term parabolic move, many are viewing the current price action as a strategic opportunity to gain leverage through miners before anticipated blowout earnings.

Aflac, Inc. is a holding company, which engages in the provision of financial protection services. It operates through the following segments: Aflac Japan and Aflac U.S. The Aflac Japan segment offers life insurance, death benefits, and cash surrender values. The Aflac U.S. segment sells voluntary supplemental insurance products for people who already have major medical or primary insurance coverage. The company was founded by John Amos, Paul Amos and William Amos on November 17, 1955 and is headquartered in Columbus, GA.

Aflac Inc.

Aflac is trending as investors debate the potential for a stock split given its long-term stability and performance, while closely watching upcoming earnings and dividend growth. The community remains focused on whether Aflac's recent operational milestones and consistent dividend hikes can continue to drive shareholder value in a fluctuating insurance sector.

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Neogenomics Inc.

Neogenomics is trending as investors react to a string of positive analyst upgrades and strong earnings results, which have reinforced confidence in its oncology testing platform and expanded market opportunities. The community is actively discussing the stock's potential for further re-rating, with many focusing on raised guidance, the launch of new cancer-tracking tests, and the possibility of the company becoming an attractive acquisition target.

Darling Ingredients, Inc. engages in the development and production of natural ingredients from edible and inedible bio-nutrients. It operates through the following segments: Feed Ingredients, Food Ingredients, and Fuel Ingredients. The Feed Ingredients segment includes ingredients such as fats and proteins used cooking oil, trap grease and food residuals collection, the Rothsay ingredients, and specialty products. The Food Ingredients segment consists of gelatin, natural casings and meat by-products, and specialty products activities. The Fuel Ingredients segment includes the bioenergy business. The company was founded in 1882 and is headquartered in Irving, TX.

Darling Ingredients Inc

Darling Ingredients is experiencing heightened investor interest driven by strong Q1 earnings results and positive momentum in its core specialty ingredients business. The community is actively discussing the company's strategic growth through its renewable diesel joint venture and ongoing sustainability initiatives, which remain key catalysts for the current bullish sentiment.

Progressive Corp. is an insurance holding company, which engages in the provision of personal and commercial auto insurance, residential property insurance, and other specialty property-casualty insurance and related services. It operates through the following segments: Personal Lines, Commercial Lines, and Property. The Personal Lines segment includes agency and direct businesses. The Commercial Lines segment writes primary liability and physical damage insurance for automobiles and trucks owned and operated predominately by small business in the auto, for-hire transportation, contractor, for-hire specialty, tow, and for-hire livery markets. The Property segment covers residential property insurance for homeowners, other property owners, and renters. The company was founded on March 10, 1937, and is headquartered in Mayfield Village, OH.

Progressive Corp.

Progressive Corp

Progressive Corp (PGR) is drawing market attention as investors weigh its role as a defensive, low-leverage insurance leader amid broader market volatility and high interest rates. Community discussions are heavily focused on its strong return on equity and competitive valuation relative to industry peers, with some traders actively monitoring insider trading windows and technical indicators for potential breakout opportunities.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. is attracting significant community attention due to its unique combination of rare earth magnet production, battery recycling, and a specialized technology-driven supply chain model that aims to reduce reliance on foreign markets. Retail investors are closely monitoring the stock's volatility and low-float dynamics, with many speculating that its specialized positioning in the domestic critical minerals sector could lead to sustained momentum.

Polygon

Polygon (POL) is seeing a surge in community engagement driven by the network's pivot toward institutional payment infrastructure and RWA tokenization. Investors are actively debating the token's long-term utility versus recent price underperformance, while many look toward potential regulatory catalysts and increased network burn rates as indicators of a future rally.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Equity

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. It operates through the following geographical segments: Chinese Mainland, USA, and Other Regions. The company was founded by Yu Xia, Peng Zhang, Baiyong Li, and Zhongmin Wang in March 2012 and is headquartered in Zhongshan, China.

Current Price	$16.00
Prev Close	$16.85
Open	$16.60
Dividend Yield	0.00%
50-Day Moving Average	$16.39
Beta	0.00
Avg. Volume	558.33
PE Ratio	-93.35

52-Week High	$23.15
52-Week Low	$9.60
Market Capitalization	$14.72B
EPS (Annual)	-$0.1715
Price to Book	11.37
Revenue Per Employee	$113,045.68

AKESF
Akeso Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKESF News

AKESFAkeso Inc